MPX International's wholly-owned subsidiary, MPX Australia has been awarded a Medicinal Cannabis Licence from the Australian Office of Drug Control.
"The licence authorizes MPX Australia to undertake certain activities at the company's 70,000 sq. ft. site under construction in Launceston in Tasmania," the team with the company explains. "These include the cultivation of cannabis plants for producing cannabis or cannabis resin for medical purpose; the production of cannabis or cannabis resin for medical purposes."
"Activities related to the cultivation or production of cannabis including, but not limited to, obtaining cannabis plants, packaging, transport, storage, testing, possession and control of all resulting cannabis products as well as the supply of all cannabis plants, cannabis or cannabis resin."
"This regulatory approval is a significant milestone for our operations in Australia and is a testament to our dedication to operating in real-time and our ability to execute on our strategy," said W. Scott Boyes, Chairman, President and CEO of MPX International. "Australia provides an important gateway for MPXI into both the Oceania and Asia-Pacific markets, and we are thrilled to receive this licence, signalling another step forward in our business there."
For more information:
MPX International Corporation
5255 Yonge Street, #701, North York M2N 6P4
416-840-3725
[email protected]
mpxbioceutical.com